Literature DB >> 19917991

Lower serum lipid levels are related to respiratory impairment in patients with ALS.

A Chiò1, A Calvo, A Ilardi, E Cavallo, C Moglia, R Mutani, A Palmo, R Galletti, K Marinou, L Papetti, G Mora.   

Abstract

BACKGROUND: Recently hyperlipidemia was reported to be related to a significantly better outcome in amyotrophic lateral sclerosis (ALS). To investigate this, we evaluated the status of blood lipids in a large Italian series of patients with ALS, and assessed the effect of hyperlipidemia on patients' survival.
METHODS: The study population included 658 patients with ALS consecutively observed in 2 Italian ALS centers between 2000 and 2006. They were compared to a series of 658 healthy subjects, matched by age and gender.
RESULTS: The mean levels of total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and the LDL/HDL ratio were similar in patients with ALS and controls. Total cholesterol, HDL, triglyceride, and LDL/HDL ratio levels showed a significant decrease in patients with forced vital capacity <70% compared to those with FVC >or=90%. For each level of ALS-FRS, poorer respiratory function was related to a lower LDL/HDL ratio. Univariate survival analysis did not find any significant effect of LDL/HDL ratio on survival, either when comparing patients with ratios <or=2.99 vs >2.99 or patients in the first quartile of LDL/HDL ratio (<or=1.67) vs those in the fourth quartile (>2.79). No dose-response was found for LDL/HDL ratio subdividing patients into 5 quintiles.
CONCLUSION: Our findings do not support the observation that patients with amyotrophic lateral sclerosis have hyperlipidemia or that hyperlipidemia in this population is related to longer survival. However, some evidence emerged that respiratory impairment, but not a worse clinical status or a lower body mass index, is related to a decrease in blood lipids and LDL/HDL ratio.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19917991     DOI: 10.1212/WNL.0b013e3181c1df1e

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  53 in total

1.  Body mass index delineates ALS from FTD: implications for metabolic health.

Authors:  R M Ahmed; E Mioshi; J Caga; M Shibata; M Zoing; L Bartley; O Piguet; J R Hodges; M C Kiernan
Journal:  J Neurol       Date:  2014-06-24       Impact factor: 4.849

2.  Hypolipidemia in patients with amyotrophic lateral sclerosis: a possible gender difference?

Authors:  Ji Won Yang; Sung-Min Kim; Hee-Juang Kim; Jee-Eun Kim; Kyung Seok Park; Seung-Hyun Kim; Kwang-Woo Lee; Jung-Joon Sung
Journal:  J Clin Neurol       Date:  2013-04-04       Impact factor: 3.077

Review 3.  Clinical diagnosis and management of amyotrophic lateral sclerosis.

Authors:  Orla Hardiman; Leonard H van den Berg; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2011-10-11       Impact factor: 42.937

Review 4.  Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis.

Authors:  Seward B Rutkove
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

5.  Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System.

Authors:  Beatrice A Golomb; Abril Verden; Alexis K Messner; Hayley J Koslik; Keith B Hoffman
Journal:  Drug Saf       Date:  2018-04       Impact factor: 5.606

6.  Changes in routine laboratory tests and survival in amyotrophic lateral sclerosis.

Authors:  Jessica Mandrioli; Edoardo Rosi; Nicola Fini; Antonio Fasano; Silvia Raggi; Anna Laura Fantuzzi; Giorgio Bedogni
Journal:  Neurol Sci       Date:  2017-10-04       Impact factor: 3.307

7.  Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis.

Authors:  J Dorst; P Kühnlein; C Hendrich; J Kassubek; A D Sperfeld; A C Ludolph
Journal:  J Neurol       Date:  2010-12-03       Impact factor: 4.849

8.  Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis.

Authors:  Sabrina Paganoni; Jing Deng; Matthew Jaffa; Merit E Cudkowicz; Anne-Marie Wills
Journal:  Muscle Nerve       Date:  2011-05-23       Impact factor: 3.217

Review 9.  TDP-43/FUS in motor neuron disease: Complexity and challenges.

Authors:  Erika N Guerrero; Haibo Wang; Joy Mitra; Pavana M Hegde; Sara E Stowell; Nicole F Liachko; Brian C Kraemer; Ralph M Garruto; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2016-09-28       Impact factor: 11.685

10.  Prior medical conditions and the risk of amyotrophic lateral sclerosis.

Authors:  Meinie Seelen; Perry T C van Doormaal; Anne E Visser; Mark H B Huisman; Margot H J Roozekrans; Sonja W de Jong; Anneke J van der Kooi; Marianne de Visser; Nicol C Voermans; Jan H Veldink; Leonard H van den Berg
Journal:  J Neurol       Date:  2014-07-25       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.